Grindr is projecting over five hundred and forty million dollars in revenue for 2026 — triple the one hundred and ninety-five million it generated when CEO George Arison took over in 2022 — with adjusted EBITDA margins above forty per cent and twenty-five consecutive quarters of growth. The company has 1.4 million paying users, representing nine per cent of its total base, with average revenue per user nearly doubled over the same period. Eighty per cent of the company's code is now AI-written, producing two-and-a-half-times engineering productivity gains year on year. Morgan Stanley upgraded the stock to overweight in July 2026. It still trades at approximately thirty-five per cent below peer consumer technology companies on comparable revenue and margin multiples — a persistent anomaly that Grindr's management describes as a "Grindr discount" and that the market has not corrected despite the sustained financial performance. The healthcare expansion is the strategic story: in-app access to GLP-1 medications, PrEP prescriptions, and erectile dysfunction treatments through an AI-powered bot creates a telehealth layer targeted at an LGBTQ+ population that has historically faced significant barriers to mainstream healthcare access. The market for that combination — trust, data, distribution, and an underserved population with demonstrated willingness to pay for premium in-app services — is not replicated elsewhere in consumer health tech.